Study ID: COG ACCL0933

A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)


Participants in this study are getting treatment with strong cancer fighting drugs (called chemotherapy) for Acute Myeloid Leukemia (AML) and therefore are at risk of getting an invasive fungal infection. Invasive fungal infections are infections caused by organisms called fungi that enter the blood stream and spread to different organs in the body. Chemotherapy used to treat AML severely reduces the body┬┐s natural infection fighting ability. In this study, researchers want to find out if using a newer antifungal drug called caspofungin (also called Cancidas) will be better than the current standard antifungal drug fluconazole at preventing invasive fungal infections when given to people with AML after receiving chemotherapy treatment.

Fargo Region, Sioux Falls Region
Principal Investigator:
Kayelyn Wagner, MD,Samuel Anim, MD
AML (Acute Myelogenic Leukemia), CCL
Phase III


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list